China's Inbound Medical Tourism Surge: 410K Patients in 2025, CAR-T and Oncology in the Lead
Published: April 24, 2026 | Source: China Hospitals Guide
The Story
In 2025, China welcomed 410,000 inbound medical tourists — a 38% increase year over year. That's a number large enough to reshape the global medical tourism map. And this wave isn't being driven by budget surgeries or traditional TCM retreats. The pull factors are more cutting-edge: CAR-T cell therapy, proton therapy, and advanced oncology.
This isn't a flash-in-the-pan spike. Analysis from chinamedaccess.com points to four structural drivers: cost advantages, shorter wait times, rapid pharmaceutical innovation, and a new government certification framework launched in March 2026. For patients from Southeast Asia, the Middle East, and former Soviet states, China is becoming a credible alternative to Western healthcare systems.
China Today: Why Patients Are Voting with Their Feet
Let's start with money. The same CAR-T treatment can cost an American patient $500,000 or more. In China, even with premium pricing for international patients, costs run just one-third to one-fifth of US or European rates.
Then there's time. Proton therapy wait times in the US and Europe typically run 3 to 6 months. In China, established proton centers in major cities — Shanghai, Beijing, Guangzhou — operate with wait times of roughly 2 to 4 weeks.
The pharmaceutical shift is perhaps most significant. In February 2026, a Chinese team published a 57.1% efficacy rate in a large-sample solid tumor CAR-T clinical trial — results few would have credited from a Chinese team just three years ago. Multiple domestic CAR-T products have already received approval, with more in the pipeline.
In March 2026, the Chinese government launched a new certification framework, standardizing hospital ratings for those serving international patients. This system defines requirements for hospital international departments, interpretation services, and cross-border care workflows — a real step toward reducing information asymmetry.
Asia Medical Tourism Comparison
| Dimension | China | Thailand | Malaysia | India | Turkey |
|---|---|---|---|---|---|
| 2025 Inbound Patients | 410K | 3M+ | 1.84M | 1M+ | 1.2M+ |
| YoY Growth | 38% | 15% | 22% | 20% | 25% |
| Core Specialties | Oncology, CAR-T, Proton | General Surgery, Medical Aesthetics | General Wellness, Cardiology | Cardiac, Cosmetic | Aesthetics, Hair Transplant |
| Cost Index (US=100) | 25-40 | 30-50 | 25-45 | 10-20 | 20-35 |
| Wait Time | 2-4 weeks | 1-2 weeks | 1-2 weeks | 2-3 weeks | 1-2 weeks |
| Key Strength | Biopharma, Advanced Oncology | Service Breadth, Hospitality | Value, English Proficiency | Cost-First | Aesthetics Expertise |
Sources: Chinamedaccess.com, Tourism Authority of Thailand, Malaysia Healthcare Travel Council, India Tourism Board, Turkish Ministry of Health
What This Means for the Market
China's rise challenges an old assumption: that cutt ing-edge medical care is the exclusive domain of Western systems. For patients, that's genuinely good news — a real alternative has emerged. But it also raises new questions: how do patients navigate quality across different regulatory environments?
The new March certification framework is a step in the right direction, but medical tourism history is full of destinations that rose fast and fell fast — when outcome data failed to back up the marketing promises.
Sustained growth will depend on a few factors: whether clinical outcome tracking systems mature, whether international insurance coverage expands, and whether hospital infrastructure can maintain quality standards as volumes increase. The fundamentals look solid, but there's still a long road ahead.